{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:24:56Z","timestamp":1785558296359,"version":"3.56.0"},"reference-count":30,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,11]]},"DOI":"10.20945\/2359-3997000000150","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T09:19:42Z","timestamp":1563959982000},"source":"Crossref","is-referenced-by-count":6,"title":["Pituitary gigantism: a case series from Hospital de San Jos\u00e9 (Bogot\u00e1, Colombia)"],"prefix":"10.20945","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7120-9432","authenticated-orcid":false,"given":"William Rojas","family":"Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-2562","authenticated-orcid":false,"given":"Henry Tovar","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6946-7993","authenticated-orcid":false,"given":"Andr\u00e9s Florez","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"key":"key20190724090440_B1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ghir.2016.08.002","article-title":"Genetics of gigantism and acromegaly","volume":"30-31","author":"Hannah-Shmouni","year":"2016","unstructured":"1. Hannah-Shmouni F, Trivellin G, Stratakis CA. Genetics of gigantism and acromegaly. Growth Horm IGF Res. 2016;30-31:37-41.","journal-title":"Growth Horm IGF Res"},{"issue":"6","key":"key20190724090440_B2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ando.2015.10.002","article-title":"Pituitary gigantism: causes and clinical characteristics","volume":"76","author":"Rostomyan","year":"2015","unstructured":"2. Rostomyan L, Daly AF, Beckers A. Pituitary gigantism: causes and clinical characteristics. Ann Endocrinol (Paris). 2015;76(6):643-9.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"5","key":"key20190724090440_B3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1530\/ERC-15-0320","article-title":"Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients","volume":"22","author":"Rostomyan","year":"2015","unstructured":"3. Rostomyan L, Daly AF, Petrossians P, Nachev E, Lila AR, Lecoq AL, et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer. 2015;22(5):745-57.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"key20190724090440_B4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1227\/00006123-199402000-00001","article-title":"Transsphenoidal surgery for pituitary adenomas in children","volume":"34","author":"Dyer","year":"1994","unstructured":"4. Dyer EH, Civit T, Visot A, Delalande O, Derome P. Transsphenoidal surgery for pituitary adenomas in children. Neurosurgery. 1994;34(2):207-12; discussion 12.","journal-title":"Neurosurgery"},{"issue":"1","key":"key20190724090440_B5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MED.0000000000000212","article-title":"Pituitary gigantism: update on molecular biology and management","volume":"23","author":"Lodish","year":"2016","unstructured":"5. Lodish MB, Trivellin G, Stratakis CA. Pituitary gigantism: update on molecular biology and management. Curr Opin Endocrinol Diabetes Obes. 2016;23(1):72-80.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"5","key":"key20190724090440_B6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11102-016-0732-3","article-title":"Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening","volume":"19","author":"Mangupli","year":"2016","unstructured":"6. Mangupli R, Rostomyan L, Castermans E, Caberg JH, Camperos P, Krivoy J, et al. Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening. Pituitary. 2016;19(5):507-14.","journal-title":"Pituitary"},{"issue":"2","key":"key20190724090440_B7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF03347049","article-title":"Complete biochemical control and pituitary adenoma disappearance in a child with gigantism: efficacy of octreotide therapy","volume":"34","author":"Ciresi","year":"2011","unstructured":"7. Ciresi A, Amato MC, Galluzzo A, Giordano C. Complete biochemical control and pituitary adenoma disappearance in a child with gigantism: efficacy of octreotide therapy. J Endocrinol Invest. 2011;34(2):162-3.","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"key20190724090440_B8","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1210\/jcem.85.10.6870","article-title":"Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center","volume":"85","author":"Barrande","year":"2000","unstructured":"8. Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab. 2000;85(10):3779-85.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"key20190724090440_B9","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1210\/jc.2007-2283","article-title":"Treatment of pituitary gigantism with the GH receptor antagonist pegvisomant","volume":"93","author":"Goldenberg","year":"2008","unstructured":"9. Goldenberg N, Racine MS, Thomas P, Degnan B, Chandler W, Barkan A. Treatment of pituitary gigantism with the GH receptor antagonist pegvisomant. J Clin Endocrinol Metab. 2008;93(8):2953-6.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20190724090440_B10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1055\/s-2007-956172","article-title":"Pegvisomant treatment in gigantism caused by a GH-secreting giant pituitary adenoma","volume":"115","author":"M\u00fcssig","year":"2007","unstructured":"10. M\u00fcssig K, Gallwitz B, Honegger J, Strasburger CJ, Bidlingmaier M, Machicao F, et al. Pegvisomant treatment in gigantism caused by a GH-secreting giant pituitary adenoma. Exp Clin Endocrinol Diabetes. 2007;115(3):198-202.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"key20190724090440_B11","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1111\/apa.13269","article-title":"Colombian reference growth curves for height, weight, body mass index and head circumference","volume":"105","author":"Dur\u00e1n","year":"2016","unstructured":"11. Dur\u00e1n P, Merker A, Brice\u00f1o G, Col\u00f3n E, Line D, Abad V, et al. Colombian reference growth curves for height, weight, body mass index and head circumference. Acta Paediatr. 2016;105(3):e116-25.","journal-title":"Acta Paediatr"},{"issue":"11","key":"key20190724090440_B12","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","unstructured":"12. Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-51.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20190724090440_B13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000357673","article-title":"Paediatric pituitary adenomas: a decade of change","volume":"81","author":"Guaraldi","year":"2014","unstructured":"13. Guaraldi F, Storr HL, Ghizzoni L, Ghigo E, Savage MO. Paediatric pituitary adenomas: a decade of change. Horm Res Paediatr. 2014;81(3):145-55.","journal-title":"Horm Res Paediatr"},{"key":"key20190724090440_B14","article-title":"GH-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes","author":"Nagata","year":"2017","unstructured":"14. Nagata Y, Inoshita N, Fukuhara N, Yamaguchi-Okada M, Nishioka H, Iwata T, et al. GH-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes. Pituitary. 2017.","journal-title":"Pituitary"},{"issue":"5","key":"key20190724090440_B15","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1515\/jpem-2015-0269","article-title":"Pituitary gigantism: a retrospective case series","volume":"29","author":"Creo","year":"2016","unstructured":"15. Creo AL, Lteif AN. Pituitary gigantism: a retrospective case series. J Pediatr Endocrinol Metab. 2016;29(5):597-602.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"6","key":"key20190724090440_B16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.4158\/EP15611.OR","article-title":"Pituitary gigantism \u2013 Experience of a single center from Western India","volume":"21","author":"Patt","year":"2015","unstructured":"16. Patt HP, Bothra N, Goel AH, Kasaliwal R, Lila AR, Bandgar TR, et al. Pituitary gigantism \u2013 Experience of a single center from Western India. Endocr Pract. 2015;21(6):621-8.","journal-title":"Endocr Pract"},{"issue":"3","key":"key20190724090440_B17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11102-011-0335-y","article-title":"Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly","volume":"15","author":"Tutuncu","year":"2012","unstructured":"17. Tutuncu Y, Berker D, Isik S, Ozuguz U, Akbaba G, Kucukler FK, et al. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary. 2012;15(3):398-404.","journal-title":"Pituitary"},{"issue":"5","key":"key20190724090440_B18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1507\/endocrj.EJ12-0417","article-title":"Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism","volume":"60","author":"Shimatsu","year":"2013","unstructured":"18. Shimatsu A, Teramoto A, Hizuka N, Kitai K, Ramis J, Chihara K. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism. Endocr J. 2013;60(5):651-63.","journal-title":"Endocr J"},{"issue":"5","key":"key20190724090440_B19","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","unstructured":"19. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327-35.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20190724090440_B20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/eje.1.01956","article-title":"Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl","volume":"153","author":"Rix","year":"2005","unstructured":"20. Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur J Endocrinol. 2005;153(2):195-201.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"key20190724090440_B21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4158\/EP14330.OR","article-title":"Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY","volume":"21","author":"Freda","year":"2015","unstructured":"21. Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr Pract. 2015;21(3):264-74.","journal-title":"Endocr Pract"},{"issue":"9","key":"key20190724090440_B22","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1210\/jc.2005-2671","article-title":"Clinical characterization of familial isolated pituitary adenomas","volume":"91","author":"Daly","year":"2006","unstructured":"22. Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab. 2006;91(9):3316-23.","journal-title":"J Clin Endocrinol Metab"},{"issue":"25","key":"key20190724090440_B23","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa1408028","article-title":"Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation","volume":"371","author":"Trivellin","year":"2014","unstructured":"23. Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014;371(25):2363-74.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20190724090440_B24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1530\/ERC-15-0038","article-title":"X-linked acrogigantism syndrome: clinical profile and therapeutic responses","volume":"22","author":"Beckers","year":"2015","unstructured":"24. Beckers A, Lodish MB, Trivellin G, Rostomyan L, Lee M, Faucz FR, et al. X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Relat Cancer. 2015;22(3):353-67.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"key20190724090440_B25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1752-8062.2010.00254.x","article-title":"Familial isolated pituitary adenomas: from genetics to therapy","volume":"4","author":"Guaraldi","year":"2011","unstructured":"25. Guaraldi F, Salvatori R. Familial isolated pituitary adenomas: from genetics to therapy. Clin Transl Sci. 2011;4(1):55-62.","journal-title":"Clin Transl Sci"},{"issue":"7","key":"key20190724090440_B26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.tem.2010.02.007","article-title":"Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA)","volume":"21","author":"Chahal","year":"2010","unstructured":"26. Chahal HS, Chapple JP, Frohman LA, Grossman AB, Korbonits M. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab. 2010;21(7):419-27.","journal-title":"Trends Endocrinol Metab"},{"issue":"8","key":"key20190724090440_B27","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/humu.21292","article-title":"Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families","volume":"31","author":"Igreja","year":"2010","unstructured":"27. Igreja S, Chahal HS, King P, Bolger GB, Srirangalingam U, Guasti L, et al. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat. 2010;31(8):950-60.","journal-title":"Hum Mutat"},{"issue":"7","key":"key20190724090440_B28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1575-0922(09)72456-8","article-title":"AIP mutations in familial and sporadic pituitary adenomas: local experience and review of the literature","volume":"56","author":"Fajardo-Monta\u00f1ana","year":"2009","unstructured":"28. Fajardo-Monta\u00f1ana C, Daly AF, Riesgo-Su\u00e1rez P, G\u00f3mez-Vela J, Tichomirowa MA, Camara-G\u00f3mez R, et al. [AIP mutations in familial and sporadic pituitary adenomas: local experience and review of the literature]. Endocrinol Nutr. 2009;56(7):369-77.","journal-title":"Endocrinol Nutr"},{"issue":"3","key":"key20190724090440_B29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2265.2012.04445.x","article-title":"Familial pituitary adenomas \u2013 who should be tested for AIP mutations?","volume":"77","author":"Korbonits","year":"2012","unstructured":"29. Korbonits M, Storr H, Kumar AV. Familial pituitary adenomas \u2013 who should be tested for AIP mutations? Clin Endocrinol (Oxf). 2012;77(3):351-6.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"key20190724090440_B30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1530\/EJE-11-0304","article-title":"High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas","volume":"165","author":"Tichomirowa","year":"2011","unstructured":"30. Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol. 2011;165(4):509-15.","journal-title":"Eur J Endocrinol"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T09:20:03Z","timestamp":1563960003000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S2359-39972019005006104&lng=en&nrm=iso"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,11]]},"references-count":30,"alternative-id":["10.20945\/2359-3997000000150"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000150","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,11]]}}}